Literature DB >> 31620281

Single institutional experience of radiation therapy for angiosarcoma of the scalp without cervical lymph node metastases: Impact of concurrent chemoradiation with maintenance chemotherapy using taxanes on patient prognosis.

Hiroki Ihara1, Tatsuya Kaji2, Kuniaki Katsui3, Tomoko Miyake2, Takahiro Waki1, Norihisa Katayama4, Hidenobu Matsuzaki5, Osamu Yamasaki2, Masahiro Kuroda6, Shin Morizane2, Susumu Kanazawa4.   

Abstract

Cutaneous angiosarcoma is a rare aggressive malignant tumor. Concurrent chemoradiation (CCRT) with maintenance chemotherapy using taxanes is one of the primary treatments. The aim of the present study was to retrospectively analyze the efficacy of CCRT with maintenance chemotherapy using taxanes in localized angiosarcoma of the scalp without cervical lymph node metastases. A total of 19 patients treated with radiation therapy for localized angiosarcomas of the scalp without cervical lymph node metastases were enrolled. The overall survival (OS), progression-free survival (PFS), and local control (LC) rates were calculated using Kaplan-Meier analysis. Univariate analyses were performed for various potential prognostic factors for OS, PFS, and LC. The median radiation dose was 70 Gy (range, 60-70 Gy), and the fractional dose was 2 Gy. Radiation therapy alone, radiation therapy + interleukin-2, surgery + CCRT with maintenance chemotherapy, CCRT with maintenance chemotherapy, and CCRT without maintenance chemotherapy were administered to 2, 4, 2, 9 and 2 patients, respectively. The 1- and 3-year OS, PFS, and LC rates were 88 and 52%, 47 and 33%, and 74 and 56%, respectively. CCRT with maintenance chemotherapy and surgery were significant prognostic factors for PFS (P=0.036 and 0.025, respectively). Therefore, CCRT with maintenance chemotherapy using taxanes might be effective in treating localized angiosarcomas of the scalp without cervical lymph node metastases.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  angiosarcoma; concurrent chemoradiation with maintenance chemotherapy; prognosis; scalp; taxanes

Year:  2019        PMID: 31620281      PMCID: PMC6787943          DOI: 10.3892/mco.2019.1918

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  20 in total

1.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

Authors:  Nicolas Penel; Binh Nguyen Bui; Jacques-Olivier Bay; Didier Cupissol; Isabelle Ray-Coquard; Sophie Piperno-Neumann; Pierre Kerbrat; Charles Fournier; Sophie Taieb; Marta Jimenez; Nicolas Isambert; Frédéric Peyrade; Christine Chevreau; Emmanuelle Bompas; Etienne G C Brain; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

2.  Single institutional experience of the treatment of angiosarcoma of the face and scalp.

Authors:  Y Miki; T Tada; R Kamo; M N Hosono; H Tamiya; Y Shimatani; S Tsutsumi; R Ogino; Y Miki
Journal:  Br J Radiol       Date:  2013-10       Impact factor: 3.039

Review 3.  Cutaneous angiosarcoma.

Authors:  William M Mendenhall; Charles M Mendenhall; John W Werning; John D Reith; Nancy P Mendenhall
Journal:  Am J Clin Oncol       Date:  2006-10       Impact factor: 2.339

4.  Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan.

Authors:  Takamichi Ito; Hiroshi Uchi; Takeshi Nakahara; Gaku Tsuji; Yoshinao Oda; Akihito Hagihara; Masutaka Furue
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-25       Impact factor: 4.553

5.  Definitive Radiation Therapy for Angiosarcoma of the Face and Scalp.

Authors:  Gen Suzuki; Hideya Yamazaki; Hideya Takenaka; Norihiro Aibe; Koji Masui; Takuya Kimoto; Kotoha Tatekawa; Akihiro Nakashima; Tadashi Takenaka; Jun Asai; Satoshi Komori; Makoto Wada; Norito Katoh; Kei Yamada
Journal:  In Vivo       Date:  2016 11-12       Impact factor: 2.155

6.  Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome.

Authors:  Ryohei Sasaki; Toshinori Soejima; Kazushi Kishi; Yoshinari Imajo; Saeko Hirota; Norihiko Kamikonya; Masao Murakami; Tetsuya Kawabe; Yasuo Ejima; Akira Matsumoto; Kazuo Sugimura
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-03-15       Impact factor: 7.038

7.  Survival outcomes for cutaneous angiosarcoma of the scalp versus face.

Authors:  Jonathan M Bernstein; Jonathan C Irish; Dale H Brown; David Goldstein; Peter Chung; Albiruni R Abdul Razak; Charles Catton; Ralph W Gilbert; Patrick J Gullane; Brian O'Sullivan
Journal:  Head Neck       Date:  2017-04-11       Impact factor: 3.147

8.  Radiation therapy for angiosarcoma.

Authors:  Jon R Ward; Steven J Feigenberg; Nancy Price Mendenhall; Robert B Marcus; William M Mendenhall
Journal:  Head Neck       Date:  2003-10       Impact factor: 3.147

9.  Successful treatment of pulmonary metastasis and local recurrence of angiosarcoma with docetaxel.

Authors:  Rieko Isogai; Akira Kawada; Yoshinori Aragane; Tadashi Tezuka
Journal:  J Dermatol       Date:  2004-04       Impact factor: 4.005

10.  Cutaneous angiosarcoma of the scalp: a multidisciplinary approach.

Authors:  Timothy M Pawlik; Augusto F Paulino; Cornelius J McGinn; Laurence H Baker; Deborah S Cohen; Jeffery S Morris; Riley Rees; Vernon K Sondak
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

View more
  3 in total

Review 1.  Management of Cutaneous Angiosarcoma: an Update Review.

Authors:  Siwei Bi; Ai Zhong; Xiya Yin; Jingyi Li; Ying Cen; Junjie Chen
Journal:  Curr Treat Options Oncol       Date:  2022-02-19

2.  Radical radiotherapy for localized cutaneous angiosarcoma of the scalp.

Authors:  Atsuto Katano; Hideomi Yamashita; Keiichi Nakagawa
Journal:  Mol Clin Oncol       Date:  2021-07-21

3.  Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma.

Authors:  Amit Roy; Prashant Gabani; Elizabeth J Davis; Peter Oppelt; Emily Merfeld; Vicky L Keedy; Imran Zoberi; John S A Chrisinger; Jeff M Michalski; Brian Van Tine; Matthew B Spraker
Journal:  Clin Transl Radiat Oncol       Date:  2021-01-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.